Last reviewed · How we verify
Euglucon 5mg
At a glance
| Generic name | Euglucon 5mg |
|---|---|
| Also known as | Glibenclamide |
| Sponsor | Kyunghee University Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
- Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (PHASE4)
- Glyburide vs Glucovance in the Treatment of GDM (EARLY_PHASE1)
- Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects (PHASE4)
- The Drug -Drug Interaction of SP2086 and Glyburide (PHASE1)
- Cardioprotective Effects of GLP-1 and Their Mechanisms (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Euglucon 5mg CI brief — competitive landscape report
- Euglucon 5mg updates RSS · CI watch RSS
- Kyunghee University Medical Center portfolio CI